Loading clinical trials...

A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm | Clinical Trials | Clareo Health

COMPLETED

A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

NCT02245958•Allergan

View on ClinicalTrials.gov

Summary

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
•Treatment with Xeomin® and BOTOX® for at least 2 years each.

Exclusion Criteria

•Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
•Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.

Locations (2)

Colonia Roma Z.P., Mexico

Wakefield, United Kingdom

Key Dates

Start Date

August 1, 2015

Primary Completion Date

December 1, 2015

Completion Date

December 1, 2015

Last Updated

January 8, 2016

Enrollment

ACTUAL participants

Conditions

Cervical DystoniaBlepharospasm

Interventions

No Intervention

OTHER

Accelerating TMS for Cervical Dystonia

NCT06328114

Isolated Cervical Dystonia

View study

COMPLETEDNA

Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia

NCT03938363

Cervical Dystonia, PrimaryBlepharospasm

View study

COMPLETED

Cholinergic Receptor Imaging in Dystonia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Inclusion Criteria

Exclusion Criteria

Accelerating TMS for Cervical Dystonia

Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia

Cholinergic Receptor Imaging in Dystonia

Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing

Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia